Gut Microbiota and Metabonomics

Launched by FIRST HOSPITAL OF CHINA MEDICAL UNIVERSITY · Jan 11, 2022

Keywords

ClinConnect Summary

This clinical trial, titled "Gut Microbiota and Metabonomics," is studying how the bacteria in our gut and the substances they produce (called metabolites) relate to a specific type of stomach cancer known as Borrmann type IV gastric cancer. The researchers want to understand how these gut bacteria and metabolites affect the body, especially the organs that are targeted by the cancer. They will use advanced methods, including machine learning, to analyze this information and create models that might help in future treatments.

To participate in this trial, patients need to meet certain criteria. Eligible participants are adults aged between 65 and 75 who have been diagnosed with this type of stomach cancer by more than two specialists. They should also have a healthy weight and a good performance status, which means they can carry out daily activities with minimal help. Participants must not have taken certain medications or have other serious health conditions that could interfere with the study. If you join, you can expect to undergo tests and provide samples to help researchers learn more about the connection between gut health and cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients who sign informed consent.
• • 2. Borrmann classification of gastric cancer is determined by more than 2 pathologists.
• • 3. Patients with BMI 24-28.
• • 4. Karnofsky (KPS) score \>80.
• Exclusion Criteria:
• • 1. Patients who take any aspirin, antibiotics, prebiotics, or probiotics within 4 weeks and steroids or immunosuppressants within 6 months prior to specimen collection.
• • 2. Patients who complicate with other malignant tumors.
• • 3. Patients who complicate with diabetes, hypertension, heart disease and infectious diseases.
• • 4. Patients who complicate with inflammatory bowel disease or irritable bowel syndrome.
• • 5. Patients with metastasis.